08
May

08:00 AM EST

Medicinal Chemistry

Name: Medicinal Chemistry Strategy Meeting East Coast 2025 (Boston)
Start: 2025-05-08T08:00
End: 2025-05-08T18:00
Location: Crowne Plaza, London Docklands

Strategy Meeting East Coast USA 2025

Reinvigorating Productivity in Pharma Biotech Through Advanced Technologies and Innovative Techniques that Interrogate Activity and Mechanisms

Le Meridien Cambridge Boston

Our Event Starts In

–
days

–
hours

–
minutes

–
seconds

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Medicinal Chemistry Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Medicinal Chemistry professionals from across the East Coast, in Boston MA, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We've partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Meet Our Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Medicinal Chemistry strategy meeting.

Aimee Usera

Senior Vice President Drug Discovery Odyssey Therapeutics

Basma Hashmi

Head, Digital Solutions Takeda

Benoit Moreau

Head of Medicinal Chemistry Remix Therapeutics

Bertrand Le Bourdonnec

Chief Scientific Officer HDAX Therapeutics

Birgit Schoeberl

VP, Global Head Translational Modeling & Simulation and Data Science Novartis

Dr. Tao Guo

SVP and Head WuXi AppTec

George Naumov

Chief Operations Officer & Chief Business Officer RS Oncology

Govinda Bhisetti

Vice President and Head of Computational Chemistry Cellarity

Hajnalka Hartl

Head of Chemistry Orogen Therapeutics

Hua Xu

Director, Head of Chemical Biology and Proteomics AstraZeneca

Huseyin Mehmet

Executive Director. New Ventures University of Massachusetts Medical School

Kara Herlihy

Head of Discovery Biology Frontier Medicine

Kenneth Duncan

Former SVP, Chemistry Accent Therapeutics

Lee Fader

Vice President Congruence Therapeutics

Lu Gong

Head of Bioinformatics and AI Simcere Pharma

Marcus Semones

CSO Erez Capital

Michal Preminger

Head of Innovation East North America, Johnson & Johnson Innovation

Nicolas Triballeau

Ph.D. Director of Small Molecule Drug Discovery Revvity Signals

Rich Heidebrecht

Vice President of Research and Development Glycologix

Rocky Goldsmith

Chief Innovation Scientist / Co-Founder Congruence Therapeutics

Samantha Jeschonek

Ph.D. Sr. Product Manger Data Analytics Revvity Signals

Shankar Venkatraman

Executive Director, Chemistry IFM Therapeutics

<p>Over his 20+ year industrial career Shankar Venkatraman has invented and progressed multiple compounds through discovery and into clinical development. He has focused on discovering first-in-class small molecule modulators of new biological pathways, closely integrating medicinal chemistry, pharmacology, and safety to enter clinical trials with these novel entities. Before joining <strong>IFM Therapeutics</strong>, LLC, Shankar was a Director of Chemistry at Vitae Pharmaceuticals. There he led number of programs including Menin-MLL, resulting in Revumenib (SNDX-5613), currently undergoing multiple clinical trials for ALL/AML with an anticipated NDA filing by the end of 2023. Prior to Vitae, he was a Senior Research Fellow at Merck, where he worked on number of modalities including HIV, neuropathic pain and schizophrenia, and delivered number of clinical candidates. Before joining Merck, Shankar began his medicinal chemistry career at Axys Pharmaceuticals, and worked on cathepsin K, with efforts leading to the identification of Odanacatib. Shankar obtained his Ph.D. in synthetic organic chemistry from University of Minnesota and B.S. in chemistry from University of Bombay. He is co-author/inventor on more than 60 papers and patents.</p>

Stefan Gross

Senior Director and Head of Biochemistry Servier Pharmaceuticals

Stephanie Oestreich

Managing Director Myeloma Investment Fund

OUR AGENDA

See Which Topics Are Discussed at the Strategy Meeting

09:00 - 10:00

Roundtable Tracks

AI/ML
Generative Chemistry in Action: Applications, Challenges, and Breakthroughs

-Govinda Bhisetti
Vice President and Head of Computational Chemistry
Cellarity

Design, Synthesis & Emerging Modalities
Unlocking the Chemical Universe: The Power of DNA-Encoded Libraries in Drug Discovery

-Hajnalka Hartl
Head of Chemistry
Orogen Therapeutics

Chemical Biology, Targeted Protein Degradation And Undruggables
Beyond the Degradation Mechanism: Addressing Safety and Formulation in Targeted Therapeutics (Topic TBC)

-Andrea Zuhl
Vice President
Hyku Biosciences

Hit Identification / Lead Optimization
Fragment Based Drug Discovery

-Stefan Gross
Senior Director and Head of Biochemistry
Servier Pharmaceuticals

Strategic Partnerships In Drug Discovery
Collaborative Chemistry: The Business of Partnerships in Drug Innovation (Topic TBC)

-George Naumov
Chief Operations Officer & Chief Business Officer
RS Oncology

Integrated Drug Discovery
From Hit to Lead: Accelerating Drug Discovery Through Cutting-Edge Chemistry and Innovative Screening Strategies

-Shankar Venkatraman
Executive Director, Chemistry
IFM Therapeutics

11:10 - 12:10

Roundtable Tracks

AI/ML
Emerging Challenges in Machine Learning (ML) -Driven Molecular Property Predictions

Sponsor

Design, Synthesis & Emerging Modalities
Precision and Beyond: The Impact of Emerging Modalities on Drug Discovery and Development

-Nicolas Triballeau
Ph.D. Director of Small Molecule Drug Discovery
Revvity Signals

REVVITY SIGNALS

Chemical Biology, Targeted Protein Degradation And Undruggables
Chemoproteomics: Probing Small Molecules’ Interactions with Complex Biological Systems

-Dr. Tao Guo
SVP and Head
WuXi AppTec

WUXI APPTEC

Hit Identification / Lead Optimization
Fragment Based Drug Discovery in the Spotlight: Emerging Trends in Hit Identification and Lead Optimization

SAI

Strategic Partnerships In Drug Discovery
How Strategic Partnerships Revolutionize Pharma R&D

SAI

Integrated Drug Discovery
AI/ML Integration in the Discovery and Development of Next-Generation Therapeutics

-Samantha Jeschonek
Ph.D. Sr. Product Manger Data Analytics
Revvity Signals

REVVITY SIGNALS

12:15 - 13:15

Roundtable Tracks

AI/ML
The Evolution of AI: Looking Back at the Past 10 years and Projecting the Future 10 (Topic TBC)

-Birgit Schoeberl
VP, Global Head Translational Modeling & Simulation and Data Science
Novartis

Design, Synthesis & Emerging Modalities
Designing the Future: How De Novo Proteins are Shaping Biotechnology

Chemical Biology, Targeted Protein Degradation And Undruggables
From PROTACs to RNA-Modulated Degraders: Engineering Novel Therapeutics for Hard-to-Target Proteins

-Benoit Moreau
Head of Medicinal Chemistry
Remix Therapeutics

Hit Identification / Lead Optimization
Drugging Protein:Protein Interactions: Best practices in hit identification and lead optimization of undruggable complexes

-Aimee Usera
Senior Vice President Drug Discovery
Odyssey Therapeutics

Strategic Partnerships In Drug Discovery
Strategic Alliances and Investment Strategies: Fueling the Future of Drug Discovery (Topic TBC)

-Huseyin Mehmet
Executive Director. New Ventures
University of Massachusetts Medical School

Integrated Drug Discovery
The Next Frontier in Therapeutic RNA: Exploring Computational and AI-Driven Approaches for Target Identification, mRNA Synthesis, and Small Molecule Integration (Topic TBC)

-Bertrand Le Bourdonnec
Chief Scientific Officer
HDAX Therapeutics

14:40 - 15:10

15:10 - 16:10

Roundtable Tracks

AI/ML
Explainable AI (XAI) and ML/AL as assistive intelligence to support rational lead optimization of small molecules

-Rocky Goldsmith
Chief Innovation Scientist / Co-Founder
Congruence Therapeutics

Design, Synthesis & Emerging Modalities
Computational & AI-Driven TAA Discovery for Bispecific and Small Molecule ADC Development

-Lu Gong
Head of Bioinformatics and AI
Simcere Pharma

Chemical Biology, Targeted Protein Degradation And Undruggables
From Discovery to Application: Challenges in Using Chemical Probes for Degrader Development (Topic TBC)

-Kara Herlihy
Head of Discovery Biology
Frontier Medicine

Hit Identification / Lead Optimization
AI-Driven Drug Discovery: Transforming Hit Identification and Lead Optimization

-Lee Fader
Vice President
Congruence Therapeutics

Strategic Partnerships In Drug Discovery
The Role of Venture Partnerships in Drug Discovery

-Bertrand Le Bourdonnec
Chief Scientific Officer
HDAX Therapeutics

Integrated Drug Discovery
Blood-Brain Barrier Penetration in Drug Discovery - Challenges, Innovations, and Future Directions (Topic TBC)

-Kenneth Duncan
Former SVP, Chemistry
Accent Therapeutics

See the full agenda and facilitator line-up Download the strategy meeting brochure for full details

DOWNLOAD THE BROCHURE

Reasons To Attend the Strategy Meeting

Discussions on the advancements in targeted protein degradation and pushing past its boundaries.

Leveraging Artificial Intelligence and Machine Learning in accelerating the development of new drugs

Discuss approaches to further understand the interactions of undruggable targets and different Protein Degraders such as PROTACs, Molecular Glues, etc

Focusing on advancing interrogative techniques to improve the Drug Delivery System/Discovery: Modified mRNA, Nanoparticle-Mediated siRNA, Antibody-Drug Conjugates, and more

Become an official strategy meeting partner Whatever your business needs, we can help. Get in touch for partnering opportunities.

I'D LIKE TO PARTNER

Explore Highlight From The Past Events

Gain valuable insights, discover innovative solutions and connect with industry leaders through snapshots of our most successful gatherings.

Nov
2024

Nov
2023

May
2022

May
2021

Jun
2020

Event Gallery

Press play to hear what your colleagues had to say...

Hotel & Venue

Le Méridien Boston Cambridge

Le Méridien Cambridge-MIT’s elegant guest rooms and suites offer a place of luxurious sanctuary and unmatched comfort. Explore unique programs inspired by the brand’s European heritage. Born in a glamorous era of travel, Le Méridien believes everyone should explore the world in style.

Hotel Details Maps & Direction Parking

Quick Links

Want to find out more?

Find out more details about our Strategy Meetings and other news and events.

Here To Help

Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D Boston

Medicinal Chemistry Strategy Meeting East Coast – Boston 2024

Medicinal Chemistry

Strategy Meeting East Coast USA 2025

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Le Meridien Cambridge Boston

Fresh Medicinal Chemistry Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Meet Our Facilitators

Aimee Usera

Basma Hashmi

Benoit Moreau

Bertrand Le Bourdonnec

Birgit Schoeberl

Dr. Tao Guo

George Naumov

Govinda Bhisetti

Hajnalka Hartl

Hua Xu

Huseyin Mehmet

Kara Herlihy

Kenneth Duncan

Lee Fader

Lu Gong

Marcus Semones

Michal Preminger

Nicolas Triballeau

Rich Heidebrecht

Rocky Goldsmith

Samantha Jeschonek

Shankar Venkatraman

Stefan Gross

Stephanie Oestreich

OUR AGENDA

See Which Topics Are Discussed at the Strategy Meeting

Breakfast & Registration

Opening Keynote Presentation

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Refreshment Break

NETWORKING / 1-1 MEETINGS

NETWORKING / 1-1 MEETINGS

NETWORKING / 1-1 MEETINGS

Roundtable ( Solutions )

Roundtable Tracks

Sponsor

REVVITY SIGNALS

WUXI APPTEC

SAI

SAI

REVVITY SIGNALS

Roundtable ( Pharma/Biotech )

Roundtable Tracks

NETWORKING LUNCH

Networking / 1-1 Meetings

AFTERNOON KEYNOTE PRESENTATION

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Afternoon Refreshment Break

Panel Discussion

Drinks & Canapes Reception

Reasons To Attend the Strategy Meeting

Our 2025 Sponsors

Lead Sponsor

Thought Leader

Co-Host Sponsor

Partnering Sponsors

Exhibitor

Media Partner

Le Meridien Cambridge Boston